Grace Capital’s Dr. Reddy's Laboratories RDY Stock Holding History

Grace Capital’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-15,000	Closed	-$185K	–	154
2021 Q3	$185K	Hold	15,000	–	–	0.11%	153
2021 Q2	$221K	Hold	15,000	–	–	0.15%	127
2021 Q1	$184K	Hold	15,000	–	–	0.12%	154
2020 Q4	$214K	Hold	15,000	–	–	0.14%	145
2020 Q3	$208K	Hold	15,000	–	–	0.16%	124
2020 Q2	$159K	Hold	15,000	–	–	0.14%	133
2020 Q1	$121K	Hold	15,000	–	–	0.12%	123
2019 Q4	$122K	Buy	+15,000	New	+$118K	0.1%	135
2019 Q1	–	Sell	-15,000	Closed	-$113K	–	218
2018 Q4	$113K	Buy	15,000 +7,500	+100%	+$52.7K	0.05%	182
2018 Q3	$52K	Buy	7,500 +2,500	+50%	+$16.7K	0.02%	195
2018 Q2	$48K	Buy	+5,000	New	+$31.5K	0.02%	205

Other funds holding RDY

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Grace Capital's RDY Position: Q4 2021 in Review

Grace Capital sold out of Dr. Reddy's Laboratories (RDY) in Q4 2021, closing a stake of 15,000 shares — an estimated $185K sold.

Grace Capital first reported a position in RDY in Q2 2018 and held it in 11 quarters. The position peaked at $221K in Q2 2021. 147 funds tracked by Wall St. Rank hold RDY as of Q4 2021.

Grace Capital reported no remaining Dr. Reddy's Laboratories position as of Q4 2021 after selling out during the quarter.
Grace Capital sold 15,000 Dr. Reddy's Laboratories shares in Q4 2021, an estimated $185K.
Grace Capital first reported a position in Dr. Reddy's Laboratories in Q2 2018 and held it in 11 quarters.
Grace Capital's Dr. Reddy's Laboratories position peaked at $221K in Q2 2021.
147 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q4 2021.

Based on Grace Capital's 13F filing for Q4 2021, filed 2 Feb 2022.